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 Abstract  
Background: 
There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children.  We 
aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. 
Methods: 
We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a 
survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary 
complications, cholangiocarcinoma, liver transplantation, or death.  We analyzed patients grouped by 
disease phenotype and laboratory studies at diagnosis to identify objective predictors of long-term 
outcome.   
Results: 
We identified 781 patients, median age 12 years old, with 4277 person-years of follow-up; 33% with 
autoimmune hepatitis (AIH), 76% with inflammatory bowel disease (IBD), and 13% with small duct PSC.  
Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of 
disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, 
respectively.  Cholangiocarcinoma occurred in 1%.  Overall event-free survival was 70% at 5 years and 
53% at 10 years.  Patient groups with the most elevated total bilirubin, GGT and AST:platelet ratio index 
(APRI) at diagnosis had the worst outcomes.  In multivariate analysis PSC-IBD and small duct phenotypes 
were associated with favorable prognosis (Hazard ratio 0.6 (95%CI 0.5-0.9) and 0.7 (95%CI 0.5-0.96), 
respectively).  Age, gender and AIH overlap did not impact long-term outcome.   
Conclusions: 
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PSC has a chronic, progressive course in children.  Nearly half of patients develop an adverse liver 
outcome after 10 years of disease. Elevations in bilirubin, GGT and APRI at diagnosis can identify 
patients at highest risk.  Small duct PSC and PSC-IBD are more favorable disease phenotypes.   
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Introduction 
Primary Sclerosing Cholangitis (PSC) is a rare disease in pediatric patients, with an incidence of 0.2 cases 
per 100,000 children(1).  Existing descriptions of the natural history and characteristics of PSC are largely 
from small, single center case series with limited long-term follow-up(1-8).  Objective predictors of 
patient outcome are lacking.  We created an international consortium of pediatric liver disease centers 
to collect a large number of children with PSC and overcome these problems.  We sought to describe the 
natural history of PSC in children and to identify early laboratory, demographic and phenotypic 
predictors of long-term outcome.   
 
Methods 
Study population: 
We retrospectively reviewed medical records on all known PSC patients at 36 different institutions 
throughout Europe, North America, the Middle East, and Asia.  Potential PSC patients were identified 
from local clinical databases, regional research registries, ICD-9 and ICD-10 code searches, nationwide 
provider surveys and/or electronic medical record queries.  11 institutions providing data were non-
transplant referral centers, 13 institutions providing data were large, tertiary referral liver transplant 
centers, and 12 institutions provided population-based data that captured all patients in a defined 
geographic region.  We included all patients diagnosed with PSC before the age of 18 years.  We 
excluded patients with cholangiopathy secondary to surgical complications or  alternative systemic 
diseases(9) such as histocytosis, Wiscott-Aldrich or hyper IgM syndromes.  Several centers had 
overlapping geographic referral areas and patients could potentially have been cared for at multiple 
locations.  To account for this, we searched for and deleted duplicate instances of patients who were 
seen and enrolled at multiple study institutions.   
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Definitions and variables: 
Diagnoses were confirmed using detailed records review by physician co-investigators at the individual 
centers.  Data was abstracted and de-identified at local study sites, and reviewed and stored centrally.  
Any questions or discrepancies were reviewed between the local co-investigator and the first and senior 
authors.  The diagnosis of PSC was based on a cholestatic biochemical profile with either 
cholangiography showing multifocal stricturing and segmental dilations of the biliary tree or liver 
histopathology showing periductal, concentric fibrosis, fibro-obliterative cholangitis, or primary ductular 
involvement(9).  Patients with abnormal cholangiograms were labeled as large duct PSC.  Patients with 
normal cholangiograms but abnormal liver biopsy were labeled as small duct PSC.  Autoimmune 
hepatitis (AIH) was diagnosed in patients who met the simplified AIH criteria that have been validated in 
children (10), based on histopathology, positive autoantibodies, elevated serum globulins and exclusion 
of viral hepatitis.  All patients with a ‘probable’ or ‘definite’ score were included as AIH.   
For each patient, we collected basic demographics, general laboratory data at liver disease diagnosis 
including complete blood counts, serum chemistries, coagulation, serum globulins and autoantibody 
titers, the presence and type of associated inflammatory bowel disease (IBD), the presence of 
autoimmune hepatitis, large vs. small duct phenotype, any other co-existing immune-mediated diseases 
diagnosed at any time during available follow-up, and chronic treatment of ursodeoxycholic acid.  We 
observed that all cases of UC refractory to oral aminosalicylate monotherapy, all cases of Crohn disease, 
and all cases of AIH received systemic immunosuppression.  Physicians generally followed established 
practice guidelines for these diseases(11-13).  Patients with PSC generally did not receive 
immunosuppression outside of that mandated by coexisting IBD, AIH or other immune-mediated 
diseases.  Individual therapeutic regimens varied, and were not recorded.     
We identified several clinical endpoints: 1. the development of portal hypertensive complications 
(ascites, hepatic encephalopathy, or esophageal varices with or without bleeding), 2. biliary 
complications (a cholangitis clinical picture with a biliary stricture requiring an intervention in the form 
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of endoscopic or percutaneous stenting, balloon dilation, or drainage), 3. cholangiocarcinoma (CCA), 4. 
liver transplantation, or 5. death from liver disease.  Co-investigators reported the dates these clinical 
endpoints were first identified.   
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Analysis: 
We created a retrospective cohort of all patients and followed them from time of PSC diagnosis to each 
of endpoints 1-5 above.  A composite outcome of time free of all of 1-5 above was termed event-free 
survival.  We also analyzed survival from diagnosis of portal hypertensive or biliary complications to liver 
transplantation or liver disease-related death.  All observations were censored at the date of the last 
known clinical encounter.  We used the Kaplan-Meier method to determine 5-year and 10-year 
outcome probabilities.   
To identify early, objective laboratory predictors of long-term adverse outcomes, we compared event-
free survival, and survival with native liver in patients grouped by tertile of values of each of AST:platelet 
ratio index (APRI)(14), total bilirubin, alkaline phosphatase (ALKP), and gamma glutamyl transferase 
(GGT) at liver disease diagnosis.  Due to the wide range of normal ALKP values in children at different 
ages, we normalized all values for age using Mayo Medical Laboratories reference values(15).  We 
excluded patients who presented with portal hypertensive or biliary complications within 3 months of 
PSC diagnosis from this analysis since their baseline laboratory studies were likely reflective of the 
outcome of interest already being present.  The log-rank test assessed surv iv a l  differences 
b e tw ee n  l a b o r a t o r y  t e r t i l e s . 
We performed multivariate Cox regression to examine the association between outcome and patient 
gender, age at PSC diagnosis (<50
th
 percentile vs. ≥50
th 
percentile), the presence of large duct PSC, the 
presence of AIH, and the presence of IBD.  The proportional hazards assumption was assessed 
graphically.  All calculations were done using Stata version 13.0 (StataCorp, College Station, TX).  The 
protocol of the study was approved by the institutional review and/or research ethics board of each 
collaborating institution.   
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Results: 
Demographics and phenotype: 
We identified 781 patients with pediatric-onset PSC; 420 patients (54%) came from non-transplant 
centers or population-based cohorts, and 361 patients (46%) were identified from single-center liver 
transplant programs.  Patients were a median age of 12 years [interquartile range (IQR) 8-15] at 
diagnosis, and 39% female.  Of 751 patients who underwent at least one endoscopy (96% of cohort), IBD 
was present in 76%, 83% as ulcerative colitis or indeterminate colitis, and 17% as Crohn disease.  Large 
duct involvement was present in 87%, and 13% of patients had small duct disease.  Overlap with 
autoimmune hepatitis was present in 33%, 97% as type 1 disease (smooth muscle antibody or 
antinuclear antibody positive), and 3% (n=9) as type 2 disease (liver kidney microsomal antibody 
positive).  At least one additional comorbid immune-mediated disease was identified in 7% (52/781) of 
patients including: thyroiditis (n=11), celiac disease (n=10), type 1 diabetes (n=7), systemic vasculitis 
(n=6), juvenile idiopathic arthritis (n=5), epidermolysis bullosa (n=2), interstitial nephritis (n=2), uveitis 
(n=2), alopecia areata (n=2), and psoriasis, myasthenia gravis, and idiopathic thrombocytopenic purpura 
(n=1 each).   
 
Long-term outcomes: 
A total of 4277 person-years of follow-up was available.  Individual patients were followed for a median 
of 4.4 years [IQR 2-7.9] after PSC diagnosis.  Portal hypertensive complications occurred in 163 patients: 
present in 5% of patients at PSC diagnosis and 38% after 10 years of disease.  Biliary complications 
occurred in 95 patients: present in 5% of patients at PSC diagnosis and in 25% after 10 years of disease.  
73% (113/226) of patients with either complication were subsequently transplanted.  The median 
survival with native liver after development of a portal hypertensive or biliary complication was 2.8 and 
3.5 years, respectively.   
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CCA developed in 8 patients at an age range of 15-18 years, a median of 6 years after initial PSC diagnosis.  
Three patients had metastatic cancer and died under palliative care within 5 months of CCA diagnosis.  Five 
patients had localized disease amenable to surgery; 4 underwent resection and chemotherapy and 1 
underwent liver transplantation.  All five were alive at last known follow-up, a median of 2.5 years after CCA 
diagnosis.  All patients who developed CCA had PSC without AIH overlap (100% vs. 67% in the total cohort, 
p=0.04), and most were male (88% vs. 61% in the total cohort, p=0.16).  CCA patients were otherwise similar 
to non-CCA patients in age of original liver disease diagnosis, IBD phenotype, and large vs. small duct 
phenotype. 
Liver transplantation occurred in 14% of PSC patients overall (n=113) at a median age of 15 years [IQR 
11.9-17.7], a median of 4 years [IQR 1.5-6.2] after initial liver disease diagnosis.  Survival with native liver 
was 88% (95% CI 85-91) at 5 years and 70% (95% CI 64-75) at 10 years.   
Death from liver disease occurred in 1.4% of PSC patients overall (n=11) at a median of 9 years after initial 
PSC diagnosis (range 0.4-13 years): 3 from metastatic CCA in the native liver, 2 from complications of 
end-stage liver disease in the native liver, and 6 after liver transplantation from complications of 
immunosuppression and infections.   
Overall 221 patients experienced at least one adverse liver-related outcome.  Event-free survival was 
70% (95% CI 66-74) at 5 years and 53% (95% CI 47-59) at 10 years.  Kaplan-Meier plots for each of the 
above survival outcomes are shown in Figure 1. 
 
Laboratory values at PSC diagnosis and subsequent outcome: 
APRI, GGT, ALKP and bilirubin data were available in 83% of patients.  Tertile cutoff values at the 33
rd
 
and 66
th
 percentile were: 1.4 and 2.2 times the upper limit of normal for ALKP, 142 and 309 U/L for GGT, 
0.41 and 0.86 mg/dL for bilirubin, and 0.49 and 1.33 for APRI, respectively.  Higher values of APRI, GGT 
and bilirubin were generally associated with worse long-term outcomes, shown in Figure 2.   
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 PSC subtype characteristics and outcomes: 
Demographics, initial laboratory studies, and long-term outcomes for each PSC subtype are compared in 
Table 1.  Small duct PSC (compared to large duct PSC) patients were diagnosed at younger ages, and had 
more favorable event-free survival, primarily from less patients progressing to biliary complications.   
PSC-IBD (compared to PSC without IBD) patients were more likely male, and had a markedly lower 
proportion of AIH overlap.  Patients without concomitant IBD presented with higher APRI and MELD, 
biomarkers of more advanced stages of liver disease, despite similar age at PSC diagnosis.  The total 
proportion of patients with end stage liver disease and portal hypertensive complications at baseline 
was similar in PSC and PSC-IBD patients however.  PSC-IBD patients had a slower progression to 
complications.  PSC+AIH overlap patients were more likely to be female and to have additional non-IBD 
autoinflammatory diseases such as celiac disease.  The baseline APRI was higher in patients with AIH, 
suggesting more hepatic fibrosis, but similar proportions of patients had end-stage liver disease at 
presentation and event-free survival was nearly identical in patients with and without AIH.   
 
In multivariate regression analysis, patients with small duct PSC (vs. large duct PSC) or with PSC-IBD (vs. 
no IBD) generally showed favorable outcomes, detailed in Table 2. 
 
Discussion: 
We collaborated to create a multicenter, international cohort of pediatric PSC patients of 
unprecedented size.  Our study was especially unique in that over half of patients were collected from 
smaller centers and population-based cohorts, eliminating much of the referral bias typical of rare 
disease research done only in the largest-volume, single tertiary care centers.  There were three main 
findings from this study.  First, we provided the clearest picture of the long-term outcomes in PSC 
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patients to date, with nearly half of all patients experiencing an adverse liver-related event within 10 
years of diagnosis.  Second, we showed that bilirubin, GGT and APRI at diagnosis correlate directly with a 
child’s long-term clinical outcome. Third, we characterized the differences in presentation and outcome 
between PSC subtypes of PSC+AIH, PSC-IBD, and small duct PSC.   
 
Natural History: 
Pediatric PSC has a chronic, progressive, and relentless course. Nearly half of patients will develop an 
adverse liver outcome within 10 years of diagnosis.  The identification of portal hypertensive or a biliary 
complication represents a tipping point in the natural history, with a subsequent median survival with 
native liver of only 3 years.  These outcomes occurred despite treatment of the vast majority of patients 
with chronic ursodeoxycholic acid therapy.  Effective treatments are needed to change the course of this 
disease. 
Our study is unprecedented in size, and no other comparable pediatric data exist.  Compared to 
descriptions of adult-onset PSC, pediatric disease appears milder.  The 10-year survival with native liver 
in our series was better than what is reported in large adult studies (70% vs. 61%-64%, respectively)(16, 
17).  Approximately half of children with PSC experienced an adverse liver-related outcome by 10 years 
of disease, while a majority of adults with PSC have evidence of disease progression after 5 years(18).  
Up to one third of adults with PSC may have esophageal varices within a year of diagnosis(19, 20) (13% 
in our cohort), and symptomatic dominant strictures occur in the majority of adults within 5 years of 
diagnosis(21, 22) (16% in our cohort).  Several factors may explain much of the difference in long-term 
outcomes between pediatric and adult-onset PSC.  Lead-time bias may be an important contributor as 
adult patients may experience progressive, sub-clinical disease over a longer period of time than 
children, leading to a more advanced presentation of liver disease at diagnosis.  General comorbidities 
such as obesity, fatty liver disease, alcoholic hepatitis, smoking, cardiovascular disease and diabetes are 
much more prevalent in adult patients, and may worsen overall outcomes compared to children.  Many 
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studies of adults are more biased towards tertiary care, referral populations, a problem we attempted 
to control in our multicenter cohort inclusive of a broad spectrum of PSC patients.  We speculate that 
children generally have an earlier stage of the same disease as adult patients, and if followed longer, 
their outcomes would become indistinguishable.   
CCA is a rare, but serious complication in pediatric PSC.  It occurred in 1% of children in follow-up, 
compared to 7-9% of adults(23, 24).  All cases of CCA occurred in children aged 15 years or older.  All 
children with CCA had previous or concurrent evidence of stricture requiring intervention (8% of all 
children who had treatment of a stricture at some point).   There is currently no formal guidance on 
screening children with PSC for CCA.  A combination of ultrasound and serum cancer antigen 19-9 
detected 91% of CCA in adults(25).  Practice guideline suggestions to screen PSC patients over the age of 
18 with these studies at 6-12 month intervals(26) could reasonably be extended to PSC patients aged 15 
and older, and those pediatric patients who require interventional procedures for biliary strictures.     
 
Laboratory Predictors: 
We showed that even small elevations in baseline total bilirubin, GGT and APRI at PSC diagnosis predict 
long-term clinical outcomes.  Other surrogate investigations of fibrosis predict long-term outcome in 
adults with PSC. As the enhanced liver fibrosis(ELF) score or liver stiffness via transient elastography 
progressively increased, long-term survival in PSC progressively decreased similar to the trends shown 
with APRI in our series(27, 28).  APRI, ELF and transient elastography have previously been shown to 
have similar accuracy in detecting significant fibrosis in chronic liver disease(29, 30).  Elevated bilirubin is 
associated with a poor outcome in adult patients(17), and is included in prognostic models such as the 
Mayo score(31).  We are not aware of data on elevated GGT as a prognostic marker in PSC.  Alkaline 
phosphatase carries prognostic value in adults(32-34), but did not predict outcome in children even 
when normalized for age.  ALKP is a less-reliable marker of liver disease in pediatrics due the wide 
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variability in isozyme originating from bone in growing children.  GGT is a better biochemical marker of 
biliary disease in pediatrics.   
It appears that APRI could be an indicator of hepatic fibrosis, while bilirubin and GGT are biomarkers of 
the degree of cholangiopathy present in pediatric PSC.  Patients with even mild elevation of these 
markers at baseline have more advanced disease and are likely to experience a worse outcome.    
Bilirubin, GGT and APRI may be good biomarkers for future clinical trials in children, and could serve as 
the basis for future pediatric prognostic calculators.   
 
PSC Phenotypes: 
Small duct PSC and PSC-IBD were milder phenotypes of the disease.  Disease progression was similar in 
patients regardless of gender, age at diagnosis and the presence of absence of AIH.  Small duct PSC was 
a favorable phenotype in adult series as well(16, 35, 36).  Some small duct PSC may be an earlier 
precursor to large duct PSC.  Approximately 20% of adults with small duct disease will progress to large 
duct disease over time (36, 37).  Some cases of small duct PSC may be genetically unique from large duct 
PSC(38).  We saw a similar prevalence of portal hypertensive complications and similar APRI at diagnosis 
in both small and large duct PSC phenotypes.  Despite a comparable degree of presumed fibrosis, small 
duct PSC patients progressed more slowly to end-stage disease complications. 
PSC with AIH overlap experienced the same incidence of adverse outcomes as PSC patients without 
overlap.  PSC and PSC+AIH had a similar transplant rate in a large adult series(16).  Most cases of AIH in 
children are readily treated with standard immunosuppression and have excellent outcomes(12).  The 
portal inflammation of AIH in PSC+AIH cases seems to respond to immunosuppressive therapy.  A 
prospective study of immunosuppressive treatment of children with PSC+AIH overlap showed similar 
improvement in biochemistry and portal-based inflammation on histopathology compared to children 
with AIH alone(39).  Immunosuppression did not appear to control progression of the bile duct disease 
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in these patients however, with half showing progressive cholangiopathy in follow-up.   The 10-year 
survival with native liver was 65%, similar to the overall survival in PSC and PSC+AIH in our larger series.  
The similar progression to adverse outcomes between patients with and without AIH in our multicenter 
cohort suggests that it is the degree of underlying, untreatable cholangiopathy, not the degree of 
treatable portal-based inflammation related to AIH that independently determines outcome. 
PSC-IBD carried a more favorable prognosis in our cohort as well.  PSC patients with IBD had a lower rate 
of cirrhosis and higher survival with native liver in children(2).  Adult PSC-IBD patients with a Crohn 
phenotype did markedly better in an adult series, though patients with ulcerative colitis did marginally 
worse(16).  Many patients with IBD and PSC are on immunosuppressive medications though this is 
unlikely to be the reason for improved survival.  Other studies have shown that corticosteroids, 
azathioprine, methotrexate and infliximab do not seem to affect PSC progression(9, 39-41).  The 
prevalence of AIH overlap was much higher in patients without IBD.  It is possible that concurrent 
immunosuppression for IBD masked the portal-based inflammation of AIH in some patients, incorrectly 
categorizing them as isolated cases of PSC.  Multifactorial differences in microbiome, lymphocyte 
trafficking and immune regulation along the gut-liver axis between patients with and without IBD may 
explain different disease progression.   
 
Strengths and Weaknesses: 
The strengths of this study are its large size, and inclusion of a diverse patient mix from secondary as 
well as tertiary care sites, and from multiple population-based cohorts. Overall this is a more realistic 
representation of the full spectrum of PSC seen in children.  We confirmed the diagnosis of PSC using 
detailed records review and did not rely on any administrative-level or coding data.  The weakness of 
this study is its retrospective design, with the possibility of misclassification bias.  Not all patients had all 
investigations, such as colonoscopy to look for IBD, and thus some patients have been incorrectly 
categorized.  Differences in access to care in a variety of different health systems may have influenced 
Page 16 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
the timing and choice of diagnostic procedures.  Our retrospective design limited the amount of data on 
the immunosuppression regimens used.  A meaningful analysis of the effect of immunosuppression on 
these diseases requires complete and longitudinal data on varying drug doses and drug combinations, 
serum drug levels, and patient compliance that was not available.    We presume that ill patients with 
advanced liver disease were more likely to receive regular follow-up and to be captured in this cohort. 
Unknown loss to follow-up of patients with mild disease may have artificially worsened the overall 
prognostic picture.  We did not correlate laboratory studies with cholangiography or histopathology for 
this study, but hope to do this in the future.   
 
Conclusions:  
We collaborated to describe the disease characteristics and natural history of PSC in a large, global 
cohort of children.  Adverse liver outcomes are common in children after 10 years of disease.  Most 
patients who develop portal hypertensive or biliary complications require liver transplantation within 3 
years.  Small duct PSC and PSC-IBD are favorable disease phenotypes.  Total bilirubin, GGT and APRI at 
PSC diagnosis are strongly-associated with long-term outcome.  
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Table 1: Characteristics of PSC subtypes 
 Small duct 
(n=98) 
Large duct 
(n=567) 
No IBD 
(n=180) 
PSC-IBD 
(n=571) 
No AIH 
(n=521) 
PSC+AIH 
(n=260) 
 
Demographic and phenotypic  
characteristics: 
Female gender 35% 39% 48%† 36%† 36%† 45%† 
Age at diagnosis (years) 10.5† 11.7† 10.9 11.6 11.5 11.3 
PSC only 63% 69% 49%‡ 72%‡ -- -- 
PSC + Autoimmune hepatitis  37% 31% 51%‡ 28%‡ -- -- 
Inflammatory bowel disease 69% 78% -- -- 82%‡ 63%‡ 
No IBD 31% 22% -- -- 17%‡ 37%‡ 
Large duct disease -- -- 80% 86% 86% 83% 
Small duct disease -- -- 20% 14% 14% 17% 
Non-IBD, non-AIH autoimmune 
disease 
7% 7% 4% 8% 5%† 10%† 
Ursodeoxycholic acid  
treatment 
77% 86% 84% 82% 84% 81% 
 
Laboratory studies at diagnosis: 
Hemoglobin (g/dL) 12.1 12.1 12.1 12.1 12.1 12.1 
Platelet count 323 330 260‡ 350‡ 328 320 
INR 1.14 1.11 1.2 1.1 1.1 1.2 
Total protein 7.9 7.8 7.9 7.8 7.7‡ 8.1‡ 
Albumin 4.0 4.0 3.9 4.0 4.0 4.0 
Total bilirubin 1.1 1.7 2.5‡ 1.2‡ 1.5 1.7 
Alkaline phosphatase 552 590 637 546 599 495 
ALKP (xULN) 1.3 1.4 1.6 1.3 1.5 1.2 
GGT 286 302 281 294 290 290 
ALT 222 199 286† 176† 161‡ 299‡ 
AST 235 178 293† 156† 142‡ 290‡ 
 
Globulins and autoantibodies: 
Globulin fraction 3.9 3.8 4.0 3.8 3.7‡ 4.1‡ 
IgG 2041 1918 1996 1926 1744‡ 2319‡ 
IgG4 153 132 118 154 133 190 
ANA+ 37% 52% 59% 47% 41%‡ 62%‡ 
ANCA+ 71% 66% 53%† 69%† 60%† 74%† 
SMA+ 48% 45% 58%† 42%† 34%‡ 61%‡ 
LKM+ 3% 1% 3% 1% 0%‡ 4%‡ 
 
Disease severity at diagnosis: 
APRI 0.81 0.88 1.57‡ 0.68‡ 0.71‡ 1.25‡ 
MELD score 0 1 4‡ 0‡ 1 2 
Patients with MELD ≥ 12 3% 6% 12%‡ 3%‡ 4% 7% 
Portal hypertensive 
complication at diagnosis 
7% 5% 5% 5% 5% 5% 
Biliary complication at 
diagnosis 
1% 5% 5% 3% 5% 2% 
 
Clinical endpoints: 
portal hypertensive 
complications at 5 years 
22% 23% 31%† 21%† 21% 25% 
biliary complications at 5 years 1%‡ 19%‡ 24%† 12%† 15% 12% 
5-year survival with native liver 87% 88% 86% 89% 87% 90% 
5-year event-free survival 77% 67% 58%† 73%† 71% 69% 
       
† p<0.01 for pairwise comparison, ‡ p<0.001 for pairwise comparison 
MELD = Model for End-stage Liver Disease, ANA = antinuclear antibody, ANCA = antinuclear cytoplasmic antibody, SMA = smooth muscle antibody, 
LKM = liver kidney microsomal antibody.   
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Table 2: proportional hazards analysis of phenotypic characteristics and event-free survival 
 
Predictor Reference Univariate Hazard Ratio 
HR (95%CI) 
p Multivariate Hazard Ratio 
HR (95%CI) 
p 
Male gender Female gender 0.88 (0.67-1.15) 0.342 0.90 (0.68-1.18) 0.450 
Age ≥ 12 years Age < 12 years 1.02 (0.79-1.34) 0.857 1.04 (0.80-1.36) 0.778 
Small duct PSC Large duct PSC 0.71 (0.52-0.99) 0.042 0.69 (0.50-0.96) 0.028 
AIH No AIH  1.00 (0.75-1.32) 0.990 0.89 (0.67-1.2) 0.461 
IBD No IBD 0.66 (0.49-0.89) 0.006 0.63 (0.47-0.86) 0.004 
 
Page 22 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 23 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 24 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 25 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 26 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 27 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 28 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 29 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 30 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 31 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
101x73mm (300 x 300 DPI)  
 
 
Page 32 of 31
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
